See ratings and reviews when you sign up for an account.

Genes Influencing Iron Overload State

This study is currently Recruiting

July 2011 By St. Jude Children's Research Hospital

First Recieved on July 7, 2010

Last Updated on July 6, 2011

Sponsor: St. Jude Children's Research Hospital
Information provided by: St. Jude Children's Research Hospital
Identifier: NCT01158794


Iron overload, which can be defined operationally as too much iron in the body, develops as a consequence of too many blood transfusions given, or due to genetic defects hereditary hemochromatosis).Iron accumulates in several organs in the body, such as the heart, liver, endocrine glands (pancreas, thyroid, etc.), and spleen.Excessive iron can damage organs and may even cause death. Iron overload needs to be appropriately monitored and treated to avoid unnecessary morbidity and mortality. The present study, GENIOS, proposes to test prospectively the hypothesis that genetic modifiers influence the iron overload status of patients receiving transfusions. To test this hypothesis, the study will perform genetic studies to investigate possible genetic influences for iron accumulation in the body and will study iron accumulation not only in the liver, but also in the heart, pancreas, kidneys, and spleen. In addition:the study will investigate if these same genes have any role during treatment of iron overload, in other words, if certain genetic mutations will influence how iron exits the body. This study will also investigate how substances that are known to control the trafficking of iron in and out of the body and its damaging effects to the tissues (hepcidin and non transferrin-bound iron) are linked to the accumulation of iron in the heart and liver. Iron in the body will be measured by R2*MRI and no liver biopsies will be required. Genetic studies will be done by specialized tests using peripheral blood DNA. Iron accumulates differently in different people and in different organs of the body. Some people accumulate iron faster than others, even when receiving the same number of blood transfusions

Study Type: Observational
Study Design: Observational Model: Case-Only, Time Perspective: Prospective


Ages Eligible for Study:N/A
Genders Eligible for Study:Both
Accepts Healthy Volunteers:No

Inclusion Criteria: - History of ? 12 lifetime erythrocyte transfusions who have not yet initiated treatment to unload iron (iron chelation or therapeutic phlebotomy), or - History of ? 12 lifetime erythrocyte transfusions who have initiated treatment to unload iron, but had liver iron content measurement (by R2*MRI) within 3 months prior to initiation of iron unloading treatment Exclusion Criteria - Known contraindication to performance of MRI (e.g.: presence of MRI-incompatible ferromagnetic material in the body) - Prior participation on the MRIRON protocol


  • Investigator: Jane Hankins, MD, MS - Principal Investigator - St. Jude Children's Research Hospital


  • St . Jude Children's Research Hospital

    Memphis, Tennessee 38105 United States

Conditions related to this trial:

Disclaimer: The list and ratings above are for informational purposes only, and is intended to supplement, not substitute for, the expertise and judgment of your physician, pharmacist or other healthcare professional. The goal of the information is to provide you with a comprehensive view of all available treatments, but should not be construed to indicate that use of any one treatment is safe, appropriate, or effective for you. Decisions about use of a new treatment, or about a change in your current treatment plan, should be in consultation with your doctor or other healthcare professional.